NCT00001021View on ClinicalTrials.gov

A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
BIOLOGICAL

rgp120/HIV-1IIIB

BIOLOGICAL

rgp120/HIV-1MN

Trial Locations (3)

14642

Univ of Rochester Med Ctr, Rochester

37232

Vanderbilt Univ Hosp, Nashville

63104

St Louis Univ School of Medicine, St Louis

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00001021 - A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009) | Biotech Hunter | Biotech Hunter